RSC Advances
Paper
Table 3 IC50 values of the tested compoundsa
IC50b (mM)
Guangxi Province (AB17292075) and Guangxi Funds for
Distinguished Experts.
Compound
MOVAS
HUVEC
AC16
Notes and references
2g
2t
59.14 ꢂ 2.31
94.93 ꢂ 4.57
>100
>100
>100
>100
1 (a) M. J. Fisher, B. P. Gunn, S. Um and J. A. Jakubowski,
Tetrahedron Lett., 1997, 38, 5747–5750; (b) H. Huse and
M. Whiteley, Chem. Rev., 2011, 111, 152–159; (c) D. B. Khadka
and W. J. Cho, Bioorg. Med. Chem., 2011, 19, 724–734; (d)
Z. Jin, Nat. Prod. Rep., 2013, 30, 849–868; (e) B.-R. Kang, S. Li,
S. Mao, Y.-X. Cao and S.-Q. Zhang, Bioorg. Med. Chem., 2015,
25, 5808–5812; (f) Y.-M. Ma, K. Qiao, Y. Kong, M.-Y. Li,
L.-X. Guo, Z. Miao and C. Fan, Nat. Prod. Res., 2017, 31, 951–
958; (g) J. Drogosz-Stachowicz, A. Długosz-Pokorska, K. Gach-
Janczak, A. Jaskulska, T. Janecki and A. Janecka, Chem. Biol.
Interact., 2020, 320, 109005.
a
IC50 represents the concentration that inhibits 50% of cell
b
proliferation. Each value is expressed in mM and represents the
mean of three data sets.
promoted by a hydrogen atom transfer (HAT) process. This was
similar to the above oxidation of isoquinoliniums, in that
intermediate III was oxidized to cation IV by DABCO+, (radical
cation) and then reacted with base to remove H2O2 to obtain
target product 3a.
2 (a) N. Fokialakis, P. Magiatis, A. L. Skaltsounis, F. Tillequin
The in vitro cardiovascular activities of all the synthesized
compounds were tested on several cell lines, including MOVAS
(mouse aorta vascular smooth muscle cells), HUVEC (human
umbilical vein endothelial cells) and AC16 (human cardiomyocytes
cells). As reported in Table 3, the biological activities were
expressed as IC50 values. The table shows that two products
demonstrated moderate activities of MOVAS cells with IC50 values
of 59.14 ꢂ 2.31 and 94.93 ꢂ 4.57, respectively. The results showed
that these products only had potential effects on mouse aorta
vascular smooth muscle cells. Unfortunately, the products did not
inhibit the activity of HUVEC and AC16 cells.
´
and T. Sevenet, J. Nat. Prod., 2000, 63, 1004–1005; (b)
T. S. Wu and F. W. Lin, J. Nat. Prod., 2001, 64, 1404–1407;
(c) S. Mitaku, N. Fokialakis, P. Magiatis and F. Tillequin,
Fitoterapia, 2007, 78, 169–170; (d) P. H. Coombes,
E. M. Mwangi, B. K. Peters, N. R. Crouch and
D. A. Mulholland, Biochem. Syst. Ecol., 2009, 37, 494–496;
(e) J.-Y. Cho, S.-H. Bae, H.-K. Kim, M.-L. Lee, Y.-S. Choi,
J.-Y. Cho, S.-H. Bae, H.-K. Kim, M.-L. Lee, Y.-S. Choi,
B.-R. Jin, H. J. Lee, H. Y. Jeong, Y. G. Lee and J.-H. Moon, J.
Agric. Food Chem., 2015, 63, 3587–3592.
3 (a) A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier and
M. Cushman, J. Med. Chem., 2006, 49, 7740–7753; (b) H. T. My
Van and W. J. Cho, Bioorg. Med. Chem., 2009, 19, 2551–2554.
4 (a) M. Sato, H. Kawakami, T. Motomura, H. Aramaki,
T. Matsuda, M. Yamashita, Y. Ito, Y. Matsuzaki,
K. Yamataka, S. Ikeda and H. Shinkai, J. Med. Chem., 2009,
52, 4869–4882; (b) S. Ramanathan, A. A. Mathias,
P. German and B. P. Kearney, Clin. Pharmacokinet., 2011,
50, 229–244.
5 (a) I. M. Khalil, D. Barker and B. R. Copp, J. Org. Chem., 2016,
81, 282–289; (b) T. T. Fan-Chiang, H. K. Wang and
J.-C. Hsieh, Tetrahedron, 2016, 72, 5640–5645.
6 (a) J. K. Son, S. I. Kim and Y. Jahng, Heterocycles, 2001, 55,
1981–1986; (b) D. Zewge, C. Y. Chen, C. Deer, P. G. Dormer
and D. L. Hughes, J. Org. Chem., 2007, 72, 4276–4279; (c)
J. C. Brouet, S. Gu, N. P. Peet and J. D. Williams, Synth.
Commun., 2009, 39, 1563–1569.
7 (a) A. A. Ghogare and A. Greer, Chem. Rev., 2016, 116, 9994–
10034; (b) Y.-F. Liang and N. Jiao, Acc. Chem. Res., 2017, 50,
1640–1653; (c) Y. Zhang, W. Schilling and S. Das,
ChemSusChem, 2019, 12, 2898–2910; (d) W. Schilling,
Y. Zhang, P. K. Sahoo, S. K. Sarkar, S. Gandhi,
H. W. Roesky and S. Das, Green Chem., 2021, 23, 379–387.
8 (a) Q. Liu and L. Z. Wu, Natl. Sci. Rev., 2017, 4, 359–380; (b)
A. Motaleb, A. Bera and P. Maity, Org. Biomol. Chem., 2018,
16, 5081–5085; (c) X. Zhang, K. P. Rakesh, L. Ravindar and
H. L. Qin, Green Chem., 2018, 20, 4790–4833; (d) Y. Zhou,
W. Liu, Z. Xing, J. Guan, Z. Song and Y. Peng, Org. Chem.
Front., 2020, 7, 2405–2413; (e) W. Schilling, Y. Zhang,
D. Riemer and S. Das, Chem.–Eur. J., 2020, 26, 390–395; (f)
Conclusions
In summary, we have developed the selective oxidation of Csp2–
H functionalization by employing oxygen under light-driven condi-
tions. Clearly, the ruthenium complex was used as a chemical switch
to trigger two different oxidation pathways of the N-onium salts. In
the absence of the Ru-complex, the N-functionalized onium ions
were irradiated from the a-amino radicals of tertiary amines to the
corresponding amides using air as an oxidant. On the other hand,
the quinoliniums underwent single electron transfer to form the C4-
site quinoline radical using the Ru(bpy)3Cl2 catalyst, and this was
shown to be smoothly carried out by the formation of 4-quinolones.
The outstanding advantages of these transformations are that
carbonylation at different sites of the N-methyleneiminiums could
be directly oxidized to obtain diverse ketones under air and at room
temperature.
Conflicts of interest
There are no conicts to declare.
Acknowledgements
This study was supported by the National Natural Science
Foundation of China (21977021 and 81760626), the Ministry of
Education
Innovation
Team
Fund
(IRT_16R15,
2016GXNSFGA380005), and the Natural Science Foundation of
16250 | RSC Adv., 2021, 11, 16246–16251
© 2021 The Author(s). Published by the Royal Society of Chemistry